

The challenges of Diagnosing and Treating Pelvic Inflammatory Disease

Ricardo Francalacci Savaris*

Department of Obstetrics and Gynecology, Universidade Federal do Rio Grande do Sul, Brazil

***Corresponding Author:** Ricardo Francalacci Savaris, Department of Obstetrics and Gynecology, Universidade Federal do Rio Grande do Sul, Brazil.

Received: September 27, 2024; **Published:** October 09, 2024

Keywords: *Pelvic Inflammatory Disease; Cost-Effectiveness; Diagnosis; Treatment; Tubo-Ovarian Abscess*

Pelvic Inflammatory Disease (PID) is a significant health issue that predominantly affects women of reproductive age. This condition, characterized by inflammation of the upper genital tract, can lead to serious complications such as chronic pelvic pain, infertility, and ectopic pregnancy, which may escalate into life-threatening situations. Among these complications, tubo-ovarian abscess (TOA) is particularly concerning, occurring in approximately 17% to 20% of PID cases [1-3].

The management of PID poses considerable challenges for healthcare providers and systems. A critical aspect of this management is accurate diagnosis. Once diagnosed, treatment strategies must carefully balance costs, effectiveness, and potential side effects. This balance is crucial not only in resource-limited settings but also in well-funded hospitals, where the allocation of resources can significantly impact patient care.

Diagnosing PID requires the exclusion of other conditions that may present some similarly, such as ectopic pregnancy, appendicitis, urinary tract infections, and adnexal torsion. A thorough differential diagnosis can often be achieved through patient history and physical examination, supplemented by point-of-care tests like urinary pregnancy tests and urine dipstick tests. Key factors from a patient's history include the pattern of pain, duration of symptoms, recent sexual partners, and any recent uterine procedures such as IUD placement or hysteroscopy. Physical examination findings such as rebound tenderness or adnexal masses on vaginal exam can indicate more complicated cases likely involving TOA.

In places with low resources, a complete blood count, may help physicians to infer that the patient has a tubo-ovarian abscess if the number of leukocytes is increased [4,5].

The choice of treatment for PID depends on several factors, including the severity of the disease, the presence of TOA, local antibiotic resistance patterns, and healthcare system resources. For mild to moderate cases, outpatient treatment with an intramuscular 3rd generation cephalosporin and oral antibiotics may be sufficient. If failure occurs, another intravenous antibiotic regimen is necessary. However, more severe cases, especially those involving TOA, require inpatient treatment with intravenous antibiotics and sometimes surgical intervention. The interventional radiologist may place a catheter for drainage, and the last resource is surgery.

Once decided that the most likely diagnosis is PID, the next step is to choose the antimicrobial treatment. In recent years, there has been a growing emphasis on evidence-based medicine and cost-effectiveness in healthcare decision-making. This approach is especially relevant in the treatment of PID, where multiple antibiotic regimens are available, each with its own efficacy profile and cost implications [6].

The main question is what are the most cost-effective treatments. The variations in PID incidence, treatment costs and rate of cure highlights the need for region-specific studies on cost-effectiveness. What works in one healthcare system may not be applicable to another.

From the hospital perspective, the concept of incremental cost-effectiveness ratio (ICER) evaluates different treatment strategies. The formula for ICER is simple. ICER helps decision-makers understand the additional cost required to achieve an incremental improvement in health outcomes. In the context of PID treatment, this could mean comparing the costs and effectiveness of various antibiotic regimens or treatment approaches (e.g., outpatient vs. inpatient care). The figure below explains how ICER works. The formula is applied in quadrants 2 and 3.




Figure a

Incremental cost-effectiveness plane/diagram

The resulting ICERs are presented graphically as a ratio between costs and the effectiveness/utility or as a distribution with uncertainty in cost effectiveness plane. Four quadrants represent all combinations of possible outcomes. The more effective outcomes are located further right on the x-axis, and with the rise of y-axis the cost of the outcome rises [7]. An ICER of an innovation that is more costly and more efficient than the benchmark is located in the first quadrant; in case of a more costly and less efficient technology, ICER is in the second quadrant. Other options can be derived from the figure. From Black WC [8].

Conclusion

In conclusion, managing PID is a critical area within women’s health that encompasses diagnostic challenges, clinical effectiveness considerations, cost-efficiency evaluations, and long-term health outcomes. As healthcare systems globally contend with finite resources and rising demands for care, developing evidence-based strategies for diagnosing and treating PID remains essential. Ongoing research efforts are crucial to refine diagnostic tools and optimize treatment protocols to improve health outcomes for women affected by this condition effectively. The challenge lies in translating research findings into practical guidelines applicable across diverse healthcare settings to ensure all women have access to effective and affordable PID care.

Conflict of Interest

Nothing to declare.

Bibliography

1. Golden N., *et al.* "The Use of Pelvic Ultrasonography in the Evaluation of Adolescents with Pelvic Inflammatory Disease". *American Journal of Diseases of Children* 141.11 (1987): 1235-1238.
2. Golden N., *et al.* "Pelvic Inflammatory Disease in Adolescents". *The Journal of Pediatrics* 114.1 (1989): 138-143.
3. Slap GB., *et al.* "Recognition of Tubo-Ovarian Abscess in Adolescents with Pelvic Inflammatory Disease". *The Journal of Adolescent Health: Official Publication of the Society for Adolescent Medicine* 18.6 (1996): 397-403.
4. Demirtas Omer., *et al.* "The Role of the Serum Inflammatory Markers for Predicting the Tubo-Ovarian Abscess in Acute Pelvic Inflammatory Disease: A Single-Center 5-Year Experience". *Archives of Gynecology and Obstetrics* 287.3 (2013): 519-523.
5. Ribak Rachel., *et al.* "Can the Need for Invasive Intervention in Tubo-Ovarian Abscess Be Predicted? The Implication of C-Reactive Protein Measurements". *Journal of Minimally Invasive Gynecology* 27.2 (2020): 541-547.
6. Savaris Ricardo F., *et al.* "Antibiotic Therapy for Pelvic Inflammatory Disease". *Cochrane Database of Systematic Reviews* 8.8 (2020): CD010285.
7. Parkin David. "Techniques of Economic Appraisal (including Cost-Effectiveness Analysis and Modelling, Cost-Utility Analysis, Option Appraisal and Cost-Benefit Analysis, the Measurement of Health Benefits in Terms of QALYs and Related Measures E.g. DALYs)". Faculty of Public Health HealthKnowledge (2019).
8. Black WC. "The CE Plane: A Graphic Representation of Cost-Effectiveness". *Medical Decision Making: An International Journal of the Society for Medical Decision Making* 10.3 (1990): 212-214.

Volume 13 Issue 10 October 2024

©All rights reserved by Ricardo Francalacci Savaris.